82 related articles for article (PubMed ID: 20339635)
21. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens.
Algarra R; Barba J; Merino I; Tienza A; Tolosa E; Robles JE; Zudaire J
Actas Urol Esp; 2015 Apr; 39(3):144-53. PubMed ID: 24996780
[TBL] [Abstract][Full Text] [Related]
23. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
24. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
25. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
27. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
28. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.
Williams SG; Duchesne GM; Millar JL; Pratt GR
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1082-7. PubMed ID: 15519778
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
30. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models.
Quinn DI; Henshall SM; Haynes AM; Brenner PC; Kooner R; Golovsky D; Mathews J; O'Neill GF; Turner JJ; Delprado W; Finlayson JF; Sutherland RL; Grygiel JJ; Stricker PD
J Clin Oncol; 2001 Aug; 19(16):3692-705. PubMed ID: 11504751
[TBL] [Abstract][Full Text] [Related]
32. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
33. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
34. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤ 15 ng/ml and normal digital rectal examination: a 10-year prospective follow-up study of 427 consecutive patients.
Mohamed ZK; Dominguez-Escrig J; Vasdev N; Bharathan B; Greene D
Urol Oncol; 2013 Nov; 31(8):1489-96. PubMed ID: 22591749
[TBL] [Abstract][Full Text] [Related]
37. Risk stratification of high-grade prostate cancer treated with antegrade radical prostatectomy with intended wide resection.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Tsukamoto T; Ohkubo Y; Komai Y; Ishikawa Y; Fukui I
Jpn J Clin Oncol; 2009 Jun; 39(6):387-93. PubMed ID: 19395463
[TBL] [Abstract][Full Text] [Related]
38. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.
Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Chen CH; Yu HJ; Lai MK; Cheng AL; Liu SP; Pu YS; Cheng JC
World J Surg Oncol; 2015 Nov; 13():312. PubMed ID: 26545980
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
40. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
Figg WD; Franks ME; Venzon D; Duray P; Cox MC; Linehan WM; Van Bingham W; Eastham JA; Reed E; Sartor O
World J Urol; 2004 Dec; 22(6):425-30. PubMed ID: 15592675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
